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RegulatorofMesenchyme andCancerAssociated
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BACKGROUND. Androgens and paracrine signaling from mesenchyme/stroma regulate
development and disease of the prostate, and gene profiling studies of inductive prostate
mesenchyme have identified candidate molecules such as pleiotrophin (Ptn).
METHODS. Ptn transcripts and protein were localized by in situ and immunohistochemistry
and PtnmRNAwas quantitated byNorthern blot and qRT-PCR. Ptn functionwas examined by
addition of hPTN protein to rat ventral prostate organ cultures, primary human fetal prostate
fibroblasts, prostate cancer associated fibroblasts, and BPH1 epithelia.
RESULTS. During development, Ptn transcripts and protein were expressed in ventral
mesenchymal pad (VMP) and prostatic mesenchyme. Ptn was localized to mesenchyme
surrounding ductal epithelial tips undergoing branching morphogenesis, and was located on
the surface of epithelia. hPTN protein stimulated branching morphogenesis and stromal and
epithelial proliferation, when added to rat VP cultures, and also stimulated growth of fetal
human prostate fibroblasts, prostate cancer associated fibroblasts, and BPH1 epithelia. PTN
mRNA was enriched in patient-matched normal prostate fibroblasts versus prostate cancer
associated fibroblasts. PTN also showedmale enriched expression in fetal humanmale urethra
versus female, and between wt male and ARKO male mice. Transcripts for PTN were
upregulated by testosterone in fetal human prostate fibroblasts and organ cultures of female rat
VMP. Ptn protein was increased by testosterone in organ cultures of female rat VMP and in rat
male urethra compared to female.
CONCLUSIONS. Our data suggest that in the prostate Ptn functions as a regulator
of both mesenchymal and epithelial proliferation, and that androgens regulate Ptn levels.
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INTRODUCTION
Stromal–epithelial interactions are involved in the
regulation of prostate organogenesis and tumorigene-
sis. During prostate development, androgen action
in mesenchyme regulates proliferation and differ-
entiation of the prostatic epithelium, and in turn the
epithelium regulates differentiation of the mesen-
chyme. Importantly, paracrine signaling from the
mesenchyme to the epithelium acts to (1) specify
prostatic epithelium identity, (2) induce bud formation,
(3) elicit prostatic bud growth and ductal branching,
(4) promote differentiation of secretory epithelia,
and (5) specify the types of secretory proteins that are
expressed, reviewed in Ref. [1]. This suggests that
mesenchyme is the source of potent paracrine factors,
yet few studies have endeavored to directly identify
them [2,3]. The stroma is also involved in neoplastic
prostate growth (reviewed in Ref. [4]) and cancer
associated fibroblasts (CAFs) exhibit a variety of func-
tional differences relative to normal stroma (reviewed
in [5]). Tumor stroma is no longer able to restrain
prostatic epithelial proliferation, but instead CAFs
stimulate tumor growth [6,7] and angiogenesis [8].
To determine which molecules and pathways are
active within developmental mesenchyme, we per-
formed serial analysis of gene expression (SAGE) gene
profiling of inductive mesenchyme of the ventral
mesenchymal pad (VMP) [2]. This identified mesen-
chymal expression of pleiotrophin (Ptn) and suggested
a localization to the VMP. Fgf10 [9], BMP 4 [10],
Scube1 [2], Notch2, Dlk1, [11] and Wnt 5a [3] have
previously been shown to be expressed in prostate
mesenchymeandmost of these have a functional role in
prostate organogenesis. Since androgens stimulate
prostate organogenesis via the mesenchymal compart-
ment, this has led to the hypothesis that there may be
‘‘andromedins’’ made by the mesenchyme that act
upon epithelia and which are produced in response to
androgens. However, there is no direct evidence that
‘‘andromedins’’ identified in developing prostate are
essential for androgen action, and there is controversy
regarding direct or indirect regulation [12,13].
Ptn is a secreted, highly conserved cytokine, and
belongs to a novel two member family of heparin
binding molecules, sharing structural and functional
similarities with midkine [14]. Ptn is an 18 kDa protein,
also knownas heparin affin regulatory peptide (HARP)
and heparin-binding growth-associatedmolecule (HB-
GAM). Ptn protein interacts with heparin sulfate
proteoglycans (HSPGs) at the extracellular matrix
[15]. Biological actions of Ptn are reported to be
mediated by at least three different receptors; receptor
protein tyrosine phosphatase, RPTB/x [16], syndecan-3
(N-syndecan) [17], and anaplastic lymphoma kinase
(ALK) [18]. Ptn is responsive to regulation by steroid
hormones, and Ptn transcript levels are upregulated in
the presence of dihydrotestosterone or estradiol,
in vitro and in vivo, respectively [15,19].
Ptn plays a key role in cellular growth and differ-
entiation and has been implicated as playing an
important role during development. Ptn expression is
present in tissues during late embryogenesis and
perinatal growth, and expression usually decreases
around the time of birth [20,21]. Ptn is most frequently
reported in tissues derived from mesoderm and in
organs where mesenchymal–epithelial interactions
play an important role, such as the salivary gland,
lung, pancreas, kidney, and mammary gland [22–24].
In branching organs Ptn may also be important for
branching morphogensis [25,26]. Ptn has not previ-
ously been studied in the developing prostate,
although it is reported to play a role in prostate cancer
[15]. Ptn-deficient mice have no gross anatomical
abnormalities [27] and it has been proposed that Ptn
and midkine, which are often co-expressed, might
compensate for each other [23]. Mice lacking both Ptn
and midkine show female infertility and reproductive
abnormalities though no effects upon male fertility or
reproductive anatomy were reported [28].
Ptn has diverse activity in vitro, stimulating the pro-
liferation of a wide range of cells including epithelial,
endothelial, and fibroblastic cell lines [29,30], and also
stimulates progenitor cells in primary culture to enter
lineage-specific differentiation pathways [20,31]. Ptn
expression is associated with inflammatory diseases
and tumor growth progression, and Ptn may recruit
stromal tissue and vasculature to tumors [32–35].
Ptn expression has been observed in prostate, ovarian,
testicular, pancreatic and breast cancer, solid gliomas,
neuroblastomas, melanomas, and in several malignant
cell lines of different origin, reviewed in Ref. [36].
We have examined the expression, distribution and
function of Ptn in the developing prostate, as it was
previously suggested to show mesenchymal expres-
sion [2], and we hypothesized that it may function as a
paracrine regulator of prostate development. Ptn
expression was restricted to VMP and mesenchyme of
the VP as well as the smooth muscle of the urethra. Ptn
protein was located in the mesenchyme and at the
surface of epithelial cells, and displayed a gradient
showing the highest levels at the tips of epithelial ducts.
Recombinant hPTN increased proliferation and
branching morphogenesis in cultures of VP organs
grown invitro, and stimulated the growthof fibroblasts
derived from developing prostate and prostate cancer
and prostate epithelial cells. Expression of Ptn mRNA
and protein was increased by androgens in devel-
opmental mesenchyme, and showed sexually dimor-
phic expression.
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MATERIALS ANDMETHODS
Isolation andCulture of PrimaryHumanCells
Human fetal prostate tissue was obtained following
medical termination of pregnancy. Consent was
obtained in accordance with UK guidelines and the
study was approved by the Lothian Research Ethics
Committee. The bladder and urethra were excised,
and the prostate microdissected prior to either RNA
isolation or primary culture of embryonic prostate
fibroblasts (hEPFs). Human adult prostate tissue was
obtained from patients undergoing surgery at the
Western General Hospital, Edinburgh. Primary CAFs
were derived from tissue obtained from patients at
the time of transurethral resection of the prostate
(TURP). Patient consent was obtained prior to surgery
and the study was approved by ethical review (MREC
02/5/63). To culture primary stromal cells from
embryonic or cancer samples, tissue specimens were
cut into small pieces (1mm 1mm 1mm), and
plated on a flask coated with fetal calf serum (FCS).
Primary cells were grown in DMEM supplemented
with 10% FCS and 1 penicillin/streptomycin and
CAFs were tested for tumorigenic activity in vivo [7].
Tissue Isolation FromRodents
Prostate and VMP tissues were microdissected from
the urogenital tract of Wistar rats and ARKO mice.
The day of copulatory plug observation was taken as
e0.5, and day of birth was designated P0. Animal
procedureswere conducted in accordancewithUK law
regulated by the Home Office. The P0 female bladder
and urethra were removed and dissected to isolate the
urethra adjacent to the bladder termed the VSU, which
comprised the VMP, smooth muscle, and urethral
epithelia. Additionally, P0 VMP and ventral prostate
(VP, from males) were microdissected.
ARKO mice were produced by mating female mice
heterozygous for theX-linkedhypoxanthinephosphor-
ibosyltransferase-Cre transgenewithmaleARfloxmice
[37]. This resulted in females carrying one deleted
allele and one wild-type (WT) allele of the X-linked
AR gene, which were subsequently mated to produce
ARKO males and control littermates. ARKO males
were identified by examination upon dissection and
lacked prostate and Wolffian derived organs.
RNAExtraction andQuantitative RT-PCR
Total RNA was extracted using the RNeasyTM Mini
kit (Qiagen, Crawley, UK) and RNA quality was
measured on the Agilent 2100 Bioanlayser (Agilent
Biotechnologies, Santa Clara, CA). Quantitative PCR’s
were performed on ABI 7500 machine, using the
PowerSybr PCR mastermix (ABI, Warrington, UK).
Transcript abundances were normalized to tbp/TBP
expression. The PCR primer sequences are provided
below:
NorthernBlottingAnalysis
DNA templates for Ptn (rat and human) and Gapdh
were synthesized by RT-PCR from Rat P0 UGT cDNA
or human embryonic prostate cDNA. The DNA
template was subcloned into pGEM1-Teasy Vector
(Promega, Southampton, UK). The primer sequences
were; Rn Ptn forward-GCAGTCTGAAGAGAGCTCTG,
Rn Ptn reverse-CCACTGGCAGAGACAATG and Rn
Gapdh forward-TTAGCACCCCTGGCCAAGG, Rn
Gapdh reverse-CTTACTCCTTGGAGGCCATG, Hs PTN
forward-CAGCTGTGGATACTGCTG, Hs PTN reverse-
GACAGTCTTCTGGCATTCG. Northern blot hybrid-
ization used 5 mg total RNAs asdescribed inRef. [2].We
observed one band (1.4 kb) on the Northern blot,
corresponding to the predicted size of the Rn Ptn
transcript. The intensity of the bands was quantified
using a phosphoimager, and Ptn expression was
normalized to Gapdh.
Whole-Mount In SituHybridization
The rat Ptn template was prepared by TA cloning
an 681 bp amplified PCR fragment corresponding
to nucleotides 426–1,107 into pGEM1-Teasy. RNA
probeswere prepared by in vitro transcription usingT7
and T3 RNA polymerases (DIG RNA labeling kit,
Roche, Burgess Hill, UK). Dissected rat UGT tissuewas
fixed in 4% paraformaldehyde overnight, dehydrated
through gradedmethanol and stored in 100%methanol
at 208C. RNA in situ hybridization on embryonic
and P0 urogenital tracts and cultured ventral prostates
were performed using the InsituPro VS robot (Intavis,
Bioanalytical Instruments, AG, Cologne, Germany) as
The Prostate
Gene Forward Reverse
Rn Ptn
NM_017066.2
ACTGGAAGAAGC-
AGTTTGGACC
GAGCTCTCTTCAGA-
CTGCCA
Rn Tbp
NM_013684.3
CTGGAAGGCCTT-
GTGTTGAC
GGAGAACAATTCT-
GGGTTTGA
Hs PTN
NM_002825.5
AGACTGTCACCA-
TCTCCAAG
GATCCTGTTTGCTG-
ATGTCC
Hs TBP
NM_003194.3
AGGTTAGAAGG-
CCTTGTGCTC
GGGAGGCAAGGGT-
ACATGAG
Mm Ptn
NM_008973
CAGACCATGAA-
GACTCAGAG
ACAGTCAGCATTGT-
GCAGAG
Mm Fgf10
NM_008002
GTTGTTGCCGTC-
AAAGCCAT
GCCATTGTGCTGCC-
AGTTAA
Mm Nkx3.1
NM_010921
ACAGTCAGCATT-
GTGCAGAG
ACCTGAGTGTGAGA-
GAAGGC
Mm Tbp
NM_013684.3
TGCCACACCAGC-
TTCTGAGA
GCACGAAGTGCAAT-
GGTCTTTAGG
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described in Ref. [2]. Color development times were
approximately 8 hr.
Western BlotAnalysis
Protein was isolated from frozen tissue (10–30
organs) using radioimmunoprecipitation assay (RIPA)
lysis buffer, and concentration was determined using
a Bio-Rad (Hemel Hempstead, UK) protein assay kit.
Twenty micrograms of protein extract was run on a
Bis–Tris 4–12% gel (Novex pre-cast gels, Invitrogen),
and electrotransferred overnight onto nitrocellulose
membranes (Immobilon-FL; Millipore, Bedford, MA).
The membranes were blocked for 1 hr in 5%milk/TBS,
50mM Tris–HCl, and 150mM NaCl and incubated
overnight at 48C with anti-PTN antibody (R&D
Systems, Abingdon, UK) diluted 1:100 and anti-b-
tubulin antibody (Santa Cruz Biotechnologies, Inc.,
Santa Cruz, CA) diluted 1:1,000 in 5%milk/TBST (TBS
containing 0.05% Tween-20). The membranes were
washed in TBST before addition of the appropriate
secondary antibody, goat anti-rabbit IRDye 800 (LI-COR
Biosciences, Cambridge, UK) and donkey anti-goat
Alexa fluor 680 (Invitrogen) diluted 1:10,000 in TBST.
Membranes were washed in TBST prior to scanning on
the LI-COR (LI-COR Biosciences). Antibody specificity
was confirmed by the detection of only one band at
the expected size. The intensity of the bands was then
quantified, and corrected for loading using b-tubulin.
Immunohistochemistry
For Ptn, b-catenin, SM a-actin, p63 and BrdU
immunostaining, histological sections were pressure
cooked in 10mM citric acid, pH 6.0, for 5min. Sections
to be stained with DAB were treated following a
previously published protocol [38]. Anti-Ptn antibody
(R&D Systems) was diluted 1:200, anti-SM a-actin
antibody (Sigma, Poole, UK) was diluted 1:5,000, anti-
p63 (Santa Cruz Biotechnologies, Inc.) antibody was
diluted 1:300, anti-PanCytokeratinwas diluted 1:3,000,
and anti-BrdU antibody (Fitzgerald Industries Interna-
tional, Inc., Concord, MA) was diluted 1:3,000. Ptn and
b-catenin or Ptn andp63 co-localizationwas performed
using anti-Ptn antibody diluted 1:50 and anti b-catenin
antibody (Santa Cruz Biotechnologies, Inc.) diluted
1:100 or anti-p63 antibody diluted 1:30. Antibodies
were visualizedwith a species appropriate biotinylated
secondary (Vector Laboratories, Burlingame, CA)
and avidin–alexafluor 488 or 546 (Molecular Probes,
Inc., Eugene, OR). Images were captured using a
Provis microscope (Olympus Optical Co., London,
UK) equipped with a DCS330 camera (Eastman Kodak
Co., Rochester, NY). Confocal microscopy was per-
formed on a Zeiss LSM 510 Laser scanning microscope
(Carl Zeiss Microimaging, Inc., Thornwood).
OrganCulture
Serum-free organ culture was performed as previ-
ouslydescribed [38]. P0VSUswereplaced in culture for
24 hr followed by treatment for 6 and 24 hr 108M
testosterone. P0 VPs were cultured for 6 days 108M
testosterone and 3 mg/ml recombinant human Ptn
protein (Peprotech, London, UK). Images of organ
cultures were captured on a Leica MZ6 dissecting
microscope (Leica, Deerfield, IL) with a Leica ICA
camera. Organ perimeter and size wasmeasured using
NIH image software. Organs were incubated with
100 mg/ml BrdU (Sigma) for 2 hr prior to harvesting.
Cell Culture
Cells were seeded at 2 103 cells/well in 96-well
plates (for growth assays) or 6-well plates (for RNA
preparation) and grown in DMEM supplementedwith
2% or 10% charcoal-stripped fetal calf serum (CSFCS)
and 1 penicillin/streptomycin for 24 hr. For RNA,
cells were treated testosterone (108M) for 6 or 24 hr
in duplicate. For growth assays, cells were treated with
fresh medium testosterone rhPTN 50ng/ml–1 mg/
ml for 4 days. To measure cell proliferation the Cell
Titer 96 AQueous One Solution Cell Proliferation assay
was used (Promega UK Ltd., Southampton, UK). The
Cell Titer Solution was added directly to the cells in
culture medium in a ratio of 1:6 and incubated at 378C
for 100min followed by absorbance reading at 490 nm.
RESULTS
PtnTranscript Expression in the
Developing Prostate
Ptn was identified in the rat female VMP by
LongSAGE transcriptional profiling with a ratio of
74:63 tags between theVMP/VSU [2]. TheVSUconsists
of VMP, smooth muscle and urethra and transcripts
enriched or specific to the VMP are diluted in the VSU
relative to pure VMP. Using Northern blot and qRT-
PCR, Ptn transcript levels were 2.6-fold (Northern)
(P< 0.05) and 1.5-fold (qRT-PCR, data not shown)
higher in the VMP than VSU. The temporal expression
of PtnmRNA in the prostate was studied by qRT-PCR
(Fig. 1B). Ptn was most abundant during the neonatal
(P0) and perinatal period (P4, P10) and expression
subsequently decreased until adulthood. There was
also evidence of higher Ptn levels in males versus
females at e17.5 (P< 0.001). To examine the spatial
distribution of Ptn in themale and female UGT, whole-
mount in situ hybridization was used to localize Ptn
transcripts. Ptn mRNA was observed in the female in
VMP and urethral stroma (Fig. 1C), and in the male in
the prostatic mesenchyme (all lobes) and the urethral
The Prostate
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stroma (Fig. 1D). Additionally, to determine whether
Ptn mRNA distribution was affected by testosterone,
PtnmRNAwas localized inmale VPs grown in culture
T (Fig. 1E,F). Organ growth was stimulated by
testosterone, and Ptn was present in mesenchymal
cells throughout the VP, and the distribution of Ptn
was similar between organs grown with or without
testosterone. There was no evidence of epithelial Ptn
expression (insets, Fig. 1E,F) though our studies do not
rule out low level epithelial expression or expression
within epithelial subsets.
Ptn Protein Localization in theMale and Female
Urethra and Prostate
Ptn protein was localized in the male and female
urethra and prostate by immunohistochemistry, and
showed a similar pattern to the in situ hybridization
data. Ptn was observed in the VMP, periurethral
mesenchyme and smooth muscle layer of the female
(Fig. 2A, arrows), and the mesenchyme, periurethral
mesenchyme, and smooth muscle of the prostate
(Fig. 2B). The strongest mesenchymal Ptn staining in
the VP was at the periphery. Ptn was also localized to
the ductal epithelia of the VP, where a gradient of Ptn
expression was observed; Ptn was present at the tips
of the ducts and was absent proximal to the urethra.
Additionally, Ptn expression was examined in VP
organs cultured T (Fig. 2C,D) and Ptn distribution
was similar to the VP in vivo (Fig. 2B); androgens did
not alter Ptn distribution. To examine the precise
localization of Ptn in VP epithelia, we co-localized Ptn
withb-catenin, a cell surfacemarker (Fig. 2E,F). Ptnwas
expressed in the mesenchyme of the VP, and Ptn and
b-cateninwere co-expressed at the cell surface of ductal
epithelial cells. The gradient of Ptn expression was
confirmed with strong Ptn staining at the ductal tips
and less staining proximal to the urethra. Additionally,
co-localization of Ptn with p63 showed that Ptn was
associatedwith bothp63positive andp63negative cells
(Supplementary Fig. 1). Ptn distribution was partially
inverse to the pattern associated with smooth muscle
differentiation around epithelial ducts. We propose
that, since Ptn mRNA was not observed in epithelia,
Ptn at the epithelial surface was derived from the
mesenchyme.
Ptn Is Involved in Prostatic Growth
andBranching
The role of Ptn in prostate growth and morpho-
genesis was investigated using cultures of VP organs
grown in vitro and treated with testosterone and
recombinant hPTN protein (Fig. 3A). Addition of
testosterone led to an increase in organ size and
branching; however, addition of hPTN had relatively
modest effects either in the presence or absence of
testosterone (n¼ 5 experiments, 45 organs). The two
dimensional area of VP organs grown T, 3 mg/ml
hPTN was measured using NIH imaging software
The Prostate
Fig. 1. Expression of PtnmRNA in themesenchyme ofmale and
female UGT.Panel A: Comparison of transcript levels in theVMP,
VSUandVP(P0)usingNorthernblotanalysis.Transcriptabundance
was quantified using a phosphoimager and compared with levels
expressed in the VP. The VMP exhibited a 2.6-fold enrichment
of Ptn mRNA compared with the VSU (*P< 0.05) and the VP
exhibited a 1.8-fold enrichment of Ptn mRNA compared with the
VSU. Panel B: qRT-PCR analysis of Ptn mRNA expression in the
male (m) and female (f) UGTat e17.5, and subsequent expression in
theVP at P0, P4, P10, P28 and adult prostate.PtnmRNAexpression
was significantly different in consecutive ages from e17.5 to P28
(a^eP< 0.001). Mean values were compared between the samples
using one-way ANOVA followed byTUKEYmultiple comparison.
Panels C^F: Localization of PtnmRNAusingwhole-mount in situ
hybridization in the male and female UGTand VPs grown in vitro.
Ptn mRNA expression pattern in female (C) and male (D). The
male and female UGTare oriented with the bladder on the right.
Ptn transcripts were localized to theVMP (C, arrow), and smooth
muscleof thefemaleUGT,andtheVP(D,arrow),DP,smoothmuscle
andseminalvesiclesof themaleUGT.PanelsE,F:PtnmRNAdistribu-
tion in VPs cultured in the absence or presence of testosterone.
Ptn transcripts were localized to the mesenchyme of VP cultured
T.The inset in the bottom right corner of panel F shows a magni-
fication of VP þT; no antisense probe staining was observed in
the epithelial ducts. Specimens hybridizedwith an antisense probe
(purple/blue stain) are shown in each panel, whereas the sense
probe is shown as an inset in the bottom left corner of each panel
(no signal was observed using the control sense riboprobe). DP,
dorsal prostate; URE, urethra; SM, smooth muscle; SV, seminal
vesicles. The scale bar represents 200mm in panels C and D, and
1mminpanelsEandF.
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(Fig. 3B, and Supplementary Table A). Addition of
hPTN toVPorgans hadno statistically significant effect
upon organ area, in the presence (P¼ 0.11) or absence
(P¼ 0.4) of testosterone. hPTN (Peprotech) was added
to organ cultures at physiological levels (0.94 mg/ml
tissue volume) as used previously, to determine a
functional response in vitro [39]. To investigate a
role for hPTN inbranchingmorphogenesis, the number
of epithelial bud tips around the periphery of VPs
culturedT andhPTNwere counted. The number of
tips was expressed as a ratio to organ perimeter (tips
per 1,000 pixels perimeter) to control for changes in
organ size (Fig. 3C, and values are listed in Supple-
mentary Table B). Treatment of VPs with hPTN caused
The Prostate
Fig. 2. LocalizationofPtnin themaleand femaleUGT.Thedistri-
butionofPtnprotein in themale andmale and femaleUGT (P0) and
VPorgans grown invitrowas examinedby immunohistochemistry.
TheUGTsections are orientatedso that thebladder is on theright-
handside.PanelA:PtnwasexpressedintheVMP,periurethralmes-
enchymeandsmoothmuscleof thefemaleUGT(markedbyarrows).
Panel B: Ptnwas present in themesenchyme (M) of theVP in the
male.Ptnexpressionwasalso stronglyassociatedwiththeepithelial
cells (E) at the tips of the ducts of theVP.The inset in the top right
corner shows the whole male UGTwith Ptn expression in the DP
and SV. Panels C,D: VPs cultured T exhibited mesenchymal
expression of Ptn and also association of Ptnwith surface of ductal
epithelia at the tipsof thecords.Theinset in thebottomrightcorner
shows thewholeVP organ.Testosterone did not alter Ptn distribu-
tion.Panels E,F: Ptn and b-catenin were co-localized in the male
VP, using immunofluorescence; Ptn was stained green, b-catenin
red, and co-localization of Ptn and b-catenin proteins appears
yellow.PanelE:Ptnandb-cateninwereco-localizedto theepithelial
cell surface at the tips of the prostatic ducts (yellow). Panel F:
A magnified area of the VP in panel E, showing an epithelial duct
tip. Ptn protein expression was not co-localized with b-catenin in
themesenchymeormostof theepithelialductbasementmembrane
(green arrows), and was absent from other areas of the epithelial
surface (red arrows), but was co-localized in some sub-regions
(yellowarrows).The scalebars shownare200mminpanelA, 50mm
inpanelsB^D,50mminpanelEand15mminpanelF.
Fig. 3. The effectofrecombinanthPTNonVPsgrowninvitro.P0
VPs were cultured in the presence or absence of testosterone
(108M) and/or hPTN (3mg/ml).PanelA:Whole-mountimages of
maleVP organ cultures after 6 days; addition of hPTN led to small
effectsuponorgansize andmorphology. Scalebarrepresents1mm.
Panel B: Graph showing the mean two-dimensional area of VPs
relative toT,SEM. Addition of hPTN led to amodest reduction
in the size of organs grown in the presence of T, but not in organs
grownin the absence ofT.PanelC: Graph showing themeannum-
ber of epithelial bud tips around the periphery of cultured VPs,
expressed as a ratio of organperimeter (mean number of buds per
1,000pixelsperimeterSEM).AdditionofhPTNledtoastatistically
significant (Student’s t-test, **P< 0.01and ***P< 0.001) increase in
thenumberofepithelialbudtips/unitperimeter inVPsgrownT.
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an increase in the number of tips/1,000 pixels perim-
eter in the presence (P< 0.01) or absence (P< 0.001) of
testosterone, and we suggest that Ptn has a role in
increasing branching morphogenesis in the prostate.
Ptn EffectsUponCellular Proliferation
andDifferentiation
To examine the effect of hPTN upon the cellular
differentiation and proliferation of VPs grown in vitro
(n¼ 3, 27 organs) we examined the organs by histology
and calculated proliferative rates using immunohisto-
chemistry for BrdU incorporation and stromal and
epithelial markers (Fig. 4). Histology of the VP organs
showedno substantial changes in organmorphologyor
stromal and epithelial distribution (Fig. 4A). Analysis
of stromal and epithelial differentiation using SM a-
actin and p63 showed no difference in cellular differ-
entiation after treatment with hPTN, but confirmed
increased branching of ductal tips at the periphery of
theVP organs (Supplementary Fig. 2). The proliferative
index of the epithelial and mesenchymal compart-
ments in the peripheral region (distal to the urethra)
was calculated for VPs culturedT,hPTN (Fig. 4B,C
and values are listed in Supplementary Tables C and
D). hPTN significantly increased epithelial (P< 0.05)
and stromal (P< 0.01) proliferation in the absence of
testosterone.
PTNIncreases Proliferation of Embryonic and
Cancer-Associated Fibroblasts, and BPH1Cells
The effect of hPTN upon embryonic human prostate
fibroblasts and adult CAFs was measured by prolife-
ration assay (MTT) (Fig. 5A and Supplementary
Table E). Addition of hPTN (1 mg/ml) in the absence
of testosterone and hPTN (200 ng/ml–1 mg/ml) in the
presence of testosterone, led to a statistically significant
(P< 0.01, one-way ANOVA) increase in the number
of embryonic human prostate fibroblasts. We next
examined the effect of Ptn upon the proliferation of
adult prostate CAFs. Average values for cancer
associated fibroblasts, derived from eight patients are
shown in Figure 5B (and Supplementary Table F).
Addition of recombinant hPTN protein (200 ng/ml–
1 mg/ml) in the absence of testosterone or 1 mg/ml
hPTN in the presence of testosterone led to a statisti-
cally significant increase in CAF cell number (P< 0.01)
(one-way ANOVA). To investigate the effect of hPTN
on epithelial cells we used BPH1 cells (T, hPTN
The Prostate
Fig. 4. TheeffectofhPTNoncellularproliferationintheproximal
and distal regions of the prostate.Rat VPs (P0) were grownTand
hPTN for 6 days and BrdUwas added to the culturemedium for
2hrprior toharvesting.PanelA:Histology(hematoxylinandeosin
staining) of cultured VPs after 6 days, asterisks (*) mark epithelial
buds at the periphery of the organ. Scale bar represents 100mm.
PanelB: ImmunohistochemistryofVPepithelial ductsdistal to the
urethra under different treatmentconditions showing BrdUincor-
poration (green) in the epithelial cells (red); nuclei were stained
withTopro (blue). Scalebar represents100mm.Panel C: Graphs of
BrdU incorporationSEM illustrating the rates of proliferation of
stromaandepithelia.AdditionofhPTNledtoanincreasein stromal
and epithelial cell proliferation only in the absence of testosterone
(Student’st-test, **P< 0.01).
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50 ng/ml–1 mg/ml) (Fig. 5C and Supplementary
Table G). BPH1 cells were used as a model of non-
tumorigenic human prostate epithelia which do not
express a functional androgen receptor, and thus
testosterone was not added to the treatment groups.
Addition of hPTN (1 mg/ml) to BPH1 cells led to a
statistically significant increase in cell number
(P< 0.01) (one-way ANOVA). Taken together, Ptn
protein stimulated the growth of human embryonic
fibroblasts, CAFs and BPH1 cells in the presence or
absence of testosterone.
Differential Expression of PtnmRNABetween
NormalandCancer-Associated Fibroblasts,
andMales and Females
To examine if Ptn mRNA was differentially
expressed between CAFs and NPFs, we compared
Ptn transcript levels in eight pairs of functionally tested
patient-matched NPF and CAF samples [7]. qRT-PCR
analysis (Fig. 6A) determined that there was between
1.6- and 2.5-fold (P< 0.05–0.001) less Ptn expression in
CAFs compared toNPFs in 5 of 8 samples. In samples 3
and 6, Ptn increased in CAFs versus NPFs and this
indicates the heterogeneity inherent in patient CAF
samples. CXCL12 was found to be increased in six of
eight of the CAF samples, similar to findings in breast
cancer stroma (data not shown) [40,41]. Next, we
investigatedwhetherPtn exhibited sexually dimorphic
expression in the developing human urethra and
prostate. Ptn transcript expression was compared
between the male and female human urethra (15–
18 weeks) by qRT-PCR and Northern blot. qRT-PCR
analysis of PTNmRNA expression demonstrated PTN
transcript levels were 1.5-fold higher in the male
compared to female (P< 0.001) (Fig. 6B). Northern blot
analysis determined PTN transcript expression was
2-fold higher in the male compared to female (data
not shown). PtnmRNA (P< 0.001, Fig. 1B), and protein
(1.3-fold, Fig. 6H) expression was also higher in e17.5
male versus female rat UGT, where there is little
difference in tissue morphology. We have shown
sexually dimorphic expression of Ptn in the developing
UGTandas Ptn is expressed in themesenchymeonly of
the rat and human prostate [15], it is not due to the
presence of prostatic ducts in the male and their
absence in female.
Ptn Expression Is IncreasedbyAndrogens
andAndrogen Receptor
To determine whether androgens were involved in
the regulation of Ptn mRNA expression we examined
its expression in feminized ARKO male mice that lack
AR and which cannot respond to androgens. Ptn
transcripts were measured by qRT-PCR in the UGT
of ARKO males, wt males, and wt females (Fig. 6C).
As controls, we included Nkx3.1 a gene expressed in
epithelia and known to be androgen regulated, as well
as Fgf10, a mesenchymally expressed gene unlikely to
be regulated by androgens. Nkx3.1 mRNA levels, were
substantially higher in wt males compared to ARKO
males and females (P< 0.001, one-way ANOVA)
The Prostate
Fig. 5. The effectof hPTNon cultures of humanprostate cancer
fibroblasts and BPH1 cells. Panel A: Human embryonic prostate
fibroblasts (EPFs) isolated from 15 to 18 weeks male UGTwere
grown testosterone andwith increasing amounts of hPTN (50 ^
1,000ng/ml). Panel B: Human prostate CAFs isolated from adult
maleTURP.Panel C: BPH1cells.The proliferation of the cells was
measured by MTTassay and the values at day 4 are presented and
themeasurement at 490nmis relative to the cell number. Addition
of hPTN (50ng/ml^1mg/ml) led to a significant increase in the cell
numberofEPFs,CAFsandBPH1cellsafter4daysbothinthepresence
or absence of testosterone.One-wayANOVAwithTUKEYmultiple
comparison;*P< 0.05, **P< 0.01, ***P< 0.001.
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The Prostate
Fig. 6. ExpressionofPTNmRNAinCAFsversusNPFs,maleversus femaleurethra,andregulationbyandrogens.PanelA:Theexpressionof
PTNmRNA showed a decrease in CAFs compared to NPFs in five of eight CAF/NPF pairs, when quantified by qRT-PCR.Panel B: qRT-PCR
analysis ofPTNmRNAexpression inhumanembryonicmale and femaleurethra/UGT (15 ^18weeks).The embryonicmaleUGT is exposed to
significantlyhigherlevelsofcirculating testosterone,producedby thefetaltestes, thantheembryonic femaleUGT[48].PTNmRNAlevelswere
1.5-foldhigherintheembryonicmaleversusfemaleUGT.PanelC:QuantitativePCRforPtnmRNAintheUGTofmalemice,ARKOmalemice
and femalemice. ARKOmice lack AR and are amodel for androgen action; they develop testes but lack secondary sex accessory tissues.Ptn
mRNAwaslessabundantinARKOmalesandwtfemalescomparedtowtmales.NKx3.1,anepithelialmarkerofprostateidentitywhichisknown
to be regulatedby androgens, was included as a control and showed amarked reduction in level betweenwtmales and ARKOsmales or wt
females.Fgf10, a ligandexpressedin the stroma, showedno changebetweenwtmales,ARKOmales,or females, suggesting thatitisnotandro-
gen-regulated and that the mesenchymal composition between these samples is similar. Panel D: qRT-PCR analysis of rat VSUs
grown testosterone for 6 and 24hr; testosterone increased PtnmRNAlevelsby twofold at 24hrbutnot at 6hr.Panel E: qRT-PCR for PTN
mRNAinhumanembryonicprostate fibroblasts culturedin theabsence of testosterone followedby6and24hr treatmentwith testosterone.
PTN transcriptexpressionincreasedinthepresenceof testosteroneat6hrandwaspartiallyelevatedat24hr.PanelsF,G:Westernblotanalysis
of Ptn (19kDa) and b-tubulin (50kDa);male and femaleratUGTate17.5, e19.5 and P0 (F), andVSUorgans grownin thepresence or absence of
testosterone for 24 and 48hr (G). b-tubulinwas used as the loading control and for normalization.PanelH: Quantification ofWesternblot
analysis inpanels F andG, showing folddifferenceinPtnexpressioninVSUorgansgrownTversusþT24and48hr; testosteroneincreasedPtn
levelsat24and48hrandadifferenceinPtnexpressionbetweenfemaleversusmaleratUGT(e17.5,19.05,andP0).PanelsA,B,D,E,Student’st-test;
*P< 0.05, **P< 0.01, ***P< 0.001.PanelsC,H:One-wayANOVAwithTUKEYmultiple comparison; (C) ***,þþþP< 0.001, (H)b^dP< 0.001.
consistent with its epithelial expression, while Fgf10
mRNA levels were similar in all three groups. Ptn
mRNA was 1.6-fold lower in ARKO males and wt
females (P< 0.001, one-way ANOVA), compared to wt
males, suggesting that androgens and AR increase Ptn
transcript levels (Fig. 6C). Next, we examined whether
Ptn mRNA levels were affected by testosterone using
female VMP organ rudiments grown in vitro (T).
Female VMP was cultured for 24 hr followed by 6 or
24 hr of treatment with testosterone (Fig. 6D). VMPs
(n¼ 4, 40 organs) and not VPs were used for this
experiment to minimize the potential carry over of
residual testosterone in male VPs. No changes in gross
tissue morphology of the stroma or epithelia were
observed during treatment of VMPs for 6–24 hr
in vitro. The results, expressed as fold difference in
Ptn mRNA expression relative to T were as follows:
T¼ 1 versus þT 6hr¼ 1.07 0.03 (Student’s t-test,
P¼ 0.3), T versus þT 24hr¼ 2.22 0.29 (Student’s t-
test,P¼ 0.03).Ptn transcript levelswereupregulatedby
testosterone in cultures of rat female VMP. We next
examined the effects of testosterone upon PTNmRNA
levels in primary human embryonic prostate fibroblast
cells (n¼ 3), treated T for 6 and 24 hr. The fold
difference inPTNmRNA levelswere:T¼ 1 versusþT
6 hr¼ 1.52 0.09 (Student’s t-test, P¼ 0.0082) and T
versus þT 24hr¼ 1.20 0.08 (Student’s t-test,
P¼ 0.046) (Fig. 6E). To determine if PTN mRNA
expression in CAFs was androgen-regulated, PTN
mRNA was measured in CAFs grown in the presence
or absence of testosterone for 6 or 24 hr (n¼ 3) by qRT-
PCR and Northern blotting (Supplementary Fig. 3).
PTN transcript levels in CAFs showed very small
changes in response to testosterone at any of the time
points. We determined ARmRNA and protein expres-
sion in CAFs by RT-PCR and immunohistochemistry
(data not shown), prior to performing the experiments.
We note that throughout our studies Ptn transcript
levels were detectable in females or the absence of
testosterone, and that androgens and AR increased
these levels. This suggests that there is a component of
Ptn expression which is androgen independent.
To determine whether Ptn protein expression was
regulated by androgens, we examined sexually dimor-
phic expression of Ptn and its response to androgens
in vitro. We examined Ptn protein expression in
developing male and female rat prostate/urethra
(e17.5, e19.5, and P0) using Western blot analysis, and
observed sexuallydimorphic expression (Fig. 6F).Also,
we measured Ptn in VSU organs grown T for 24 or
48 hr using Western blot analysis (Fig. 6G) (n¼ 3, 38
organs). Quantification of Ptn protein in VSU organs
grown in the presence of testosterone was expressed as
fold difference relative the absence of testosterone at
each time point. The data were as follows: T versus
þT 24hr¼ 1.6 0.1 (Student’s t-test, P¼ 0.002), T
versus þT 48hr 2.1 0.1 (Student’s t-test, P¼ 0.0003)
(Fig. 6H). The data demonstrated that Ptn protein was
upregulated by testosterone in cultures of rat female
VMP. Quantification of Ptn protein in the prostate was
expressed as fold difference relative to the female
urethra at each time point. The results were as follows:
e17.5 female versus e17.5 male¼ 1.3 0.1 (Student’s
t-test, P¼ 0.057), e19.5 female versus e19.5 male¼
2.2 0.3 (Student’s t-test, P¼ 0.014), P0 female versus
P0male¼ 2.5 0.2 (Student’s t-test, P¼ 0.007) (Fig. 6H).
Ptn protein levels showed a sexually dimorphic
expression, with higher Ptn expression in the male
versus female.
DISCUSSION
We propose that Ptn signaling is involved in
regulation of growth and branching morphogenesis
in the developing prostate, and that Ptn expression is
increased by androgens. We identified Ptn in a gene
profiling study of VMP mesenchyme [2] which is a
specialized area of mesenchyme that contains prostate
inductive activity [42]. Given the importance of VMP
mesenchyme in regulating prostate organogenesis, the
identification ofmolecules that canmediate its effects is
important and we propose that Ptn is one of many
paracrine regulators made in VMP mesenchyme that
regulate prostate growth. Ptn expression is associated
with the development of organs that are regulated by
epithelial–mesenchymal interactions andhas also been
described as a proto-oncogene. Ptn expression in the
mesenchyme plays a role in the developing kidney,
lung, and mammary gland [25,26,43], and has been
localized to the stroma of adult prostate, and prostate
cancer [15]. The role of Ptn in organogenesis has been
difficult to examine given co-expression and redun-
dancy of midkine; however, mice doubly null for Ptn
and midkine show female infertility and reproductive
abnormalities but no effects in males have been
reported [28]. Were Ptn an essential mediator of
androgen action, loss of Ptn might be expected to show
impairment of masculinization similar to that seen in
Tfm or ARKO mice, and such molecules remain to be
identified.
We suggest that Ptn is a factor that regulates the
proliferation of human and rodent prostatic stromal
and epithelial cells in developmental and disease
models. Given that transcripts for Ptn are stromal, it
suggests that Ptn functions as an autocrine regulator
of stroma and a paracrine regulator of epithelia. The
paracrine function of Ptn is supported by the local-
ization of Ptn on the surface of epithelial cells in
growing ductal tips, where Ptn protein was abundant,
in contrast to its absence from ducts proximal to the
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urethra. It will be important to establish the expression
patterns of the three receptors that bind Ptn and
transduce its signal, as this will define Ptn responsive
cells within the stromal and epithelial compartments,
and these may include key subsets of cells such as
progenitors. Co-localization of Ptn with b-catenin on
the surface of epithelial cells is notable sinceb-catenin is
a substrate of receptor protein tyrosine phosphatase
RPTB/x [16], a well-studied Ptn receptor. Ptn is known
to interact with the extracellular matrix of undiffer-
entiated cells [23] and Ptn distribution patterns similar
to our observations have been reported in the mouse
genital tubercle, where Ptn is expressed in the
mesenchyme and on the surface of epithelial cells
[23]. Ptn is also expressed in the metanephric mesen-
chyme and on the basement membrane of the uteric
budat the onset of kidneydevelopment [26].Agradient
of Ptn is present in the uteric bud, similar to our
findings in VP epithelia. Sakurai et al suggested
Ptn may be acting as ‘‘a classic morphogen’’ of the
mesenchyme that induced phenotypic changes in
epithelia according to its concentration. We observed
that Ptn had a small effect on branchingmorphogenesis
at the periphery of the developing prostate in vitro, and
established that it did not lead to mis-differentiation of
stroma or epithelia when examined by immunohisto-
chemistry for p63 or SMA (Supplementary Fig. 2).
Furthermore, addition of hPTN to VPs in culture led to
a significant increase in the number of bud tips and an
increase in the stromal and epithelial cell proliferative
rate at the periphery of the organs in the absence of
testosterone. We propose that Ptn functions as a classic
morphogen in the developing prostate, since it is made
by inductive mesenchyme of the VMP and shows
similar activities in other organs such as kidney and
genital tubercle [23,26].
Ptn has been shown to be mitogenic for a variety of
fibroblast, epithelial and endothelial cell lines, includ-
ing normal human prostate (PNT1A) and prostate
cancer epithelial lines (DU145, PC3, and LNCaP)
[15,30]. We examined the effect of hPTN on primary
human prostate embryonic fibroblasts, cancer associ-
ated fibroblasts and BPH1 cells in vitro, and found that
addition of hPTN led to a significant increase in cell
proliferation. Ptn mRNA and protein are expressed in
the stromal cells of normal adult prostate, prostate
cancer andbenignprostatic hyperplasia (BPH), andPtn
protein is also expressed in prostate tumor epithelia
[15]. Surprisingly, when we examined PTN mRNA
expression levels in matched pairs of CAFs/NPFs, five
out of eight samples showed lower levels of PTN
transcripts in CAFs compared to NPFs, and a recent
study has confirmed a reduction of PTN in reactive
prostate cancer stroma [44]. Breast cancer studies have
reported conflicting data on PTN mRNA regulation in
normal and cancer cells, reviewed inRef. [36]. Different
approaches to attenuate Ptn function in tumor cells
were found to decrease tumor growth in vivo, thus
constitutive Ptn signaling was a rate-limiting factor in
the pathogenesis of these tumors.
In thedevelopingprostate andnormal adult prostate
the effects of androgens upon epithelial cells are
mediated via AR that is expressed in the mesenchyme
or stroma, respectively [45,46]. However, there is little
knowledge of the genes and pathways that mediate
the effects of androgens on normal prostate growth or
exactly how the paracrine effects of androgens are
mediated. PTNmRNA exhibited a sexually dimorphic
pattern of expression in the human fetal prostate/
urethra; PTN transcript levels were higher in the male,
with elevated androgen levels, compared to the female.
Similarly there were lower levels of Ptn mRNA in the
urethra of female mice and ARKOmales (that lack AR)
when compared with wt male mice. Ptn protein also
showed a sexually dimorphic difference between male
and female rat urethra/prostate. Both Ptn mRNA and
protein were upregulated by testosterone in organ
cultures of the female VMP. We have shown that
androgens increase Ptn levels in several different
systems; however, Ptn expression is evident in females
or the absence of androgens, which indicates there is an
androgen independent element of Ptn expression.
Gene profiling studies have confirmed the correlation
between androgen levels and Ptn transcript levels in
the prostate [47]. Such correlative data do not provide
direct evidence for Ptn function as an ‘‘andromedin,’’
which would require direct experimental proof. Since
prostate cancer is sensitive to androgens, we examined
whether Ptn mRNA was affected by exposure to
testosterone in three CAF isolates. Surprisingly, we
found that T did not significantly alter Ptn mRNA
levels in CAFs (Supplementary Fig. 3). There are
several possible explanations for this, however, we
suggest that it may reflect dysregulation of androgen
signaling in CAFs and contributes to their pro-
tumorigenic signaling.
CONCLUSION
Our data suggest that in the prostate Ptn functions
as a regulator of both mesenchymal and epithelial
proliferation, and that androgens regulate Ptn levels.
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